T. Rowe Price Associates’s Strata Critical Medical, Inc. Class A Common Stock SRTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $122K | Buy |
30,150
+5,342
| +22% | +$21.6K | ﹤0.01% | 2855 |
|
|
2025
Q1 | $68K | Buy |
24,808
+1,955
| +9% | +$5.36K | ﹤0.01% | 2886 |
|
|
2024
Q4 | $98K | Buy |
22,853
+2,565
| +13% | +$11K | ﹤0.01% | 2824 |
|
|
2024
Q3 | $60K | Buy |
20,288
+911
| +5% | +$2.69K | ﹤0.01% | 2905 |
|
|
2024
Q2 | $68K | Buy |
19,377
+3,556
| +22% | +$12.5K | ﹤0.01% | 2810 |
|
|
2024
Q1 | $46K | Buy |
15,821
+566
| +4% | +$1.65K | ﹤0.01% | 2880 |
|
|
2023
Q4 | $54K | Buy |
15,255
+2,408
| +19% | +$8.52K | ﹤0.01% | 2799 |
|
|
2023
Q3 | $34K | Buy |
12,847
+1,280
| +11% | +$3.39K | ﹤0.01% | 2813 |
|
|
2023
Q2 | $46K | Buy |
11,567
+676
| +6% | +$2.69K | ﹤0.01% | 2807 |
|
|
2023
Q1 | $37K | Buy |
+10,891
| New | +$37K | ﹤0.01% | 2818 |
|